| |
Emtricitabine seminal plasma and blood plasma population
pharmacokinetics in HIV-infected men: results from EVARIST ANRS-EP 49
study.
Valade E, Tréluyer JM, Illamola SM, et al
Antimicrob Agents Chemother. 2015
Aug 17.
Abstract
Pharmacokinetics of Single- and Multiple-Dose Emtricitabine
in Healthy Male Chinese Volunteers.
Han WL, Shang JC, Yan B, et al
Pharmacology. 2014 May
1;93(3-4):166-171
Abstract
Population Pharmacokinetics of Emtricitabine in
HIV-1-infected Adult Patients.
Valade E, Tréluyer JM, Bouazza N, et al
Antimicrob
Agents Chemother. 2014 Feb 3.
Abstract
Pharmacokinetic Evaluation of Emtricitabine in Combination With Other
Nucleoside
Antivirals in Healthy Volunteers.
Zong J, Chittick GE, Wang LH, et al
J Clin Pharmacol. 2007 May 25;
Abstract
|
Pharmacokinetics of emtricitabine, didanosine and efavirenz administered
once-daily
for the
treatment of HIV-infected adults (pharmacokinetic
substudy of the ANRS 091
trial).
Molina JM, Peytavin G, Perusat S, et al
HIV Med. 2004 Mar;5(2):99-104.
Abstract |
| |
An Investigation of Liquid
Chromatography-Mass Spectral Attributes and Analytical
Performance Characteristics of Tenofovir, Emtricitabine and
Efavirenz in Human Plasma.
Ndolo SM, Sichilongo K, Massele A,
et al
J Anal Toxicol.
2015 Oct 20.
Abstract
Use of Micellar Liquid Chromatography to
Analyze Darunavir, Ritonavir, Emtricitabine, and Tenofovir
in Plasma
Peris-Vicente J,
Villarreal-Traver M, Casas-Breva I, et al
J Sep Sci.
2014 Aug 7.
Abstract
Selective Determination of Antiretroviral Agents Tenofovir,
Emtricitabine, and Lamivudine in Human Plasma
by a LC-MS-MS Method for a Bioequivalence Study in Healthy
Indian Subjects.
Yadav M, Singhal P, Goswami S,
et al
J Chromatogr Sci.
2010;48(9):704-13.
Abstract |
A new assay based on solid-phase extraction procedure with
LC-MS to measure plasmatic concentrations
of tenofovir and emtricitabine in HIV infected patients.
D'Avolio A, Sciandra M, Siccardi M, et al
J Chromatogr Sci. 2008 Jul;46(6):524-8.
Abstract |
|
|
Efficacy and safety of emtricitabine/tenofovir alafenamide
(FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a
backbone for treatment of HIV-1 infection in virologically suppressed
adults: subgroup analysis by third agent of a randomized, double-blind,
active-controlled phase 3 trial<sup/>.
Post FA, Yazdanpanah Y, Schembri G, et al
HIV Clin Trials. 2017 Mar
17:1-6.
Abstract
Emtricitabine + tenofovir alafenamide for the treatment of
HIV.
Corado KC, Daar ES.
Expert Opin Pharmacother. 2017 Feb
2.
Abstract
Comparison of HIV Virologic Failure Rates Between
Patients with Variable Adherence to Three Antiretroviral Regimen
Types.
Gordon LL, Gharibian
D, Chong K, Chun H.
AIDS Patient Care STDS. 2015
Jul;29(7):384-388.
Abstract
Pharmacological considerations for tenofovir and
emtricitabine to prevent HIV infection.
Anderson PL, Kiser JJ, Gardner EM,
et al
J Antimicrob Chemother.
2010 Nov 30.
Abstract |
|
Switch from zidovudine- to non-zidovudine-containing regimens is associated with
modest haematological
improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE
trial.
Lafaurie M, Collin F, Bentata M, et al
J Antimicrob Chemother. 2008 Jul
28.
Abstract
|
Prospective randomized trial of emtricitabine versus lamivudine
short-term
monotherapy in human
immunodeficiency virus-infected
patients.
Rousseau FS, Wakeford C, Mommeja-Marin H, et al.
J Infect Dis. 2003 Dec 1;188(11):1652-8.
Abstract |
|
Emtricitabine Main Page
Main
New/Newsworthy
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
